Drug Trial Radar · NCT00380250
Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation
Last checked: Nov 19, 2026Latest source record: Nov 15, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
590
Actual
Start
May 2005
Primary completion
Not stated
Study completion Jul 2006
Sponsor
- Lead sponsor
- Sucampo Pharma Americas, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Takeda
- First posted
- Sep 25, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the efficacy and safety of administration of lubiprostone in patients with irritable bowel syndrome with constipation.
Conditions
- Irritable Bowel Syndrome With Constipation
Interventions
LubiprostoneDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Responder RateTime frame: 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.